Weight loss treatments available in Ireland

They are not variations of one product. Three active ingredients, two dosing schedules, two different licensed indications, and a price range of nearly four hundred euro. Here is what actually separates them.

The five treatments compared

The three GLP-1 active ingredients used in Ireland

Tirzepatide

Acts on two receptors, GLP-1 and GIP. The dual action is the accepted explanation for why it produced the largest average weight reduction in head-to-head trial data. Only Mounjaro uses it, and it is the most expensive of the five. Mounjaro in Ireland →

Semaglutide

Acts on GLP-1 alone. Three of the five use it: Wegovy and Ozempic by injection, Rybelsus as a tablet. Same molecule, different licences and different maximum doses, which is why they cost and behave differently.

Liraglutide

The oldest of the three and shorter acting, which is why Saxenda is injected daily rather than weekly. Smaller average effect, lowest entry cost, generally the most reliable availability. Saxenda in Ireland →

Which treatments are licensed for weight loss in Ireland?

Only Wegovy, Saxenda and Mounjaro carry a weight management licence. Ozempic and Rybelsus are licensed for type 2 diabetes only, and prescribing them purely for weight loss is off-label, which many Irish prescribers decline.

If weight management is your goal, asking for Wegovy or Mounjaro rather than Ozempic makes the conversation with a prescriber considerably easier.

Which reach State reimbursement?

None of them, when prescribed for weight loss. Ozempic, Mounjaro and Rybelsus reach the €80 monthly cap when prescribed for type 2 diabetes. Wegovy and Saxenda never do, because weight management is their only indication and it is not reimbursed in Ireland.

How the Drugs Payment Scheme works →

See also: where to buy Ozempic in Ireland.

Daily or weekly weight loss injections?

Three are weekly, two are daily. It sounds minor and it is not. Adherence to daily dosing falls off faster than weekly in practice, and a treatment you stop taking does not work.

Rybelsus adds a further complication: the tablet must be taken on waking, on an empty stomach, with at least thirty minutes before anything else. For unpredictable mornings that is a real obstacle.

GLP-1 weight treatment, and what the term actually covers

The search term is usually GLP-1 weight treatment, and it groups five different medicines that share one mechanism. Glucagon-like peptide-1 is a gut hormone released after eating; these drugs imitate it, which slows stomach emptying and quietens appetite signalling.

That shared mechanism is why the side effect profiles look alike and why the results differ mainly by dose and by how strongly each molecule binds. Mounjaro adds a second receptor, GIP, which is the accepted explanation for its larger average result.

How GLP-1 treatment works in the body

All five treatments imitate a gut hormone called glucagon-like peptide-1, which your body releases after eating. Copying it produces four effects at once.

Slower stomach emptying. Food stays in the stomach longer, so fullness lasts longer after a smaller meal. This is also the main reason for the nausea people report in the first weeks.

Reduced appetite signalling. The drug acts on appetite centres in the brain, which is what people describe as the constant thinking about food quietening down.

Better insulin response. Insulin release increases when blood sugar is high and glucagon release falls, which is why these molecules were diabetes drugs before they were weight drugs.

Mounjaro adds a second target. Tirzepatide acts on GIP receptors as well as GLP-1 receptors, and that dual action is the accepted explanation for its larger average result in trials.

None of this is permanent. The effect lasts while the drug is in your system, which is why weight returns for most people after stopping and why the cost has to be planned as an ongoing one rather than a course.

Injection or tablet: what actually differs

Four of the five are injections given under the skin with a pre-loaded pen, usually in the abdomen, thigh or upper arm. The needle is short and fine, and most people describe it as unremarkable after the first two or three. Rybelsus is the only tablet.

The tablet is not simply an easier version. Oral semaglutide is poorly absorbed, so Rybelsus has to be taken on waking, on an empty stomach, with no more than 120 ml of plain water, followed by at least 30 minutes with no food, no other drink and no other tablets. Get that wrong and you absorb less of what you paid for.

So the honest trade is this: injections are a brief weekly or daily task with no rules attached, and the tablet is a daily routine with strict rules but no needle. People who will not inject choose the tablet. People who want the simplest routine choose a weekly injection.

What all five have in common

• All are prescription-only in Ireland. There is no lawful route to any of them without a prescription from a registered prescriber, and no lawful online supply of the medicine itself.
• All start low and increase. Every one of the five uses a titration schedule to reduce side effects, so the first weeks cost less and do less than maintenance.
• All produce gastrointestinal side effects early. Nausea, reflux and constipation are the common ones, and they usually settle within four to six weeks. Our guide to GLP-1 side effects covers what helps.
• All require monitoring. Baseline bloods and periodic review are standard, and are part of the cost.
• None are a short course. Stopping returns most of the lost weight for most people, so the decision is about a long-term budget, not a one-off purchase.

Who these treatments are not suitable for

This is a prescriber’s decision and not one to make from a web page, but it helps to know what will be asked. Every one of the five is contraindicated in pregnancy and while breastfeeding. All carry warnings around a personal or family history of medullary thyroid carcinoma and around multiple endocrine neoplasia type 2. A history of pancreatitis, significant kidney or liver impairment, severe gastrointestinal disease or an active eating disorder will all change the conversation.

These are also not first-line treatments for someone with a healthy BMI. Wegovy and Saxenda are licensed for weight management from a BMI of 30, or 27 with a weight-related condition such as hypertension or sleep apnoea. A prescriber who does not ask about any of this is not doing the job properly.

More on GLP-1 treatments in Ireland

All posts →

Weight loss treatments in Ireland: common questions